GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients
August 24, 2020 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Aug. 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases...
Incysus Therapeutics Initiates Enrollment in Phase 1 Study of a Genetically Modified Gamma-Delta (γδ) T Cell Immunotherapy in Patients with Newly Diagnosed Glioblastoma
February 27, 2020 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...